Europe Point of Care Diagnostics Market Outlook, 2031
The Europe Point of Care Diagnostics Market is segmented into By Product (Glucose Monitoring Kits, Infectious Diseases Testing Kits, Pregnancy And Fertility Testing Kits, Hematology Testing Kits, Cardiometabolic Monitoring Kits, Urinalysis Testing Kits, Cholesterol Test Strips, Other Products); By Technology/Platform (Lateral Flow Assays, Molecular Diagnostics (PCR/INAAT), Microfluidics & Immunoassays, Dipsticks & Test Strips); By End-User (Hospitals & Critical Care Centers, Clinical & Diagnostic Laboratories, Home Care & Self-Testing); By Mode Of Purchase (Prescription Based Products, OTC Products); By Sample (Blood, Urine, Nasal and Oropharyngeal Swabs).
- Bonafide Research
- 23-09-2026
- Pages : 105
- Figures : 9
- Tables : 28
- Region : Europe
- Category : Lifescience & Healthcare
- Medical Devices
- Schedule a Call
-
Sikandar Kesari — Research Analyst
The Europe Point of Care Diagnostics Market is expected to reach a market size of more than 19.88 Billion by 2031, driven by expanding healthcare infrastructure.
- Historical Period2020-2024
- Base Year2025
- Forecast Period2026-2031
- Market Size (2031) USD 19.88 Billion
- Largest MarketGermany
- Fastest Market Spain
- Format
Featured Companies
- 1. Abbott Laboratories
- 2. Danaher
- 3. F. Hoffmann-La Roche AG,
- 4. Siemens Healthineers
- 5. OraSure Technologies
- 6. Thermo Fisher Scientific Inc
- More...
Point of Care Diagnostics Market Analysis
The Europe Point-of-Care (POC) Diagnostics market represents decentralized medical testing performed at or near the site of patient care such as physician offices, hospital bedsides, emergency rooms, community pharmacies, and home-care settings delivering rapid, actionable results without reliance on centralized laboratories. The market is heavily driven by a rapidly aging European population, a rising prevalence of chronic conditions like diabetes and cardiovascular disease, and an escalating need for early detection of infectious diseases. The market’s strategic importance lies in its ability to drastically reduce diagnostic turnaround times, optimize patient triage in overcrowded emergency departments, and alleviate operational pressures on public healthcare systems such as the UK’s NHS. Key regional associations, including MedTech Europe and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM), play a central role in guiding industry activities. These associations advocate for harmonized reimbursement frameworks, establish quality control and clinical governance standards, and help manufacturers navigate stringent compliance challenges under the EU In Vitro Diagnostic Medical Devices Regulation (IVDR). Current industry activities focus on advancing microfluidic lab-on-a-chip technologies, expanding over-the-counter (OTC) multiplex panels for respiratory infections, and integrating AI-driven diagnostic software with cloud-connected electronic health records to support expanding telemedicine frameworks across Western and Eastern Europe. Concurrently, compliance with the EU In Vitro Diagnostic Medical Devices Regulation (IVDR) is accelerating the development of higher-grade, standardized benchtop analyzers to meet stringent clinical safety standards. Finally, strategic cross-border partnerships between medtech developers and European digital health providers are driving seamless integration of real-time diagnostic outputs directly into electronic health records and regional telemedicine networks. According to the research report, "Europe Point of Care Diagnostics Market Outlook, 2031," published by Bonafide Research, the Europe Point of Care Diagnostics Market is expected to reach a market size of more than 19.88 Billion by 2031.Major market leaders operating in the region include Roche (Switzerland), bioMérieux (France), Siemens Healthineers (Germany), Abbott Laboratories, and Danaher Corporation. High-value opportunities center on expanding over-the-counter (OTC) multiplex respiratory tests, AI-driven diagnostic tools, and microfluidic lab-on-a-chip platforms tailored for decentralized home testing. Recent industry developments reflect aggressive platform innovation, such as the UK NHS integrating AI-powered POC tools like N-Tidal for rapid respiratory diagnoses, Abbott expanding its CE-marked biosensors, and Roche acquiring LumiraDx assets to broaden its handheld decentralized testing portfolio. Supply chain analysis reveals a complex European ecosystem reliant on specialized polymer molding, microfluidic sensor fabrication, and biological reagent synthesis across regional clusters in Germany, France, and Switzerland. However, manufacturers face heightened operational friction and supply chain re-engineering due to strict regulatory compliance under the EU In Vitro Diagnostic Medical Devices Regulation (IVDR) and mandatory Joint Clinical Assessments (JCAs), prompting leaders to nearshore reagent production, secure local component sourcing, and partner with regional pharmacy networks to ensure resilient distribution across member states. National healthcare initiatives such as the UK NHS expanding virtual wards and community diagnostic hubs are increasingly incorporating connected POC analyzers to decrease emergency hospital readmissions by up to 20%.
to Download this information in a PDF
What's Inside a Bonafide Research`s industry report?
A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.
Download SampleMarket Dynamics
Market Drivers
• Strategic shift toward decentralized healthcare and public cost containment: European public health systems such as the UK’s National Health Service (NHS) and national insurance systems in France and Germany are facing severe strain from emergency department overcrowding, prolonged laboratory turnaround times, and rising operational costs. To mitigate these pressures, regional health authorities are actively funding decentralized diagnostic initiatives. Transitioning screening protocols to community diagnostic hubs, urgent care clinics, retail pharmacies, and virtual wards allows clinicians to rapidly triage patients and make real-time treatment decisions.• Epidemiological shifts driven by an aging population and chronic disease burden: Europe currently maintains one of the world's oldest demographic profiles, resulting in a rising prevalence of complex chronic health conditions. High incidence rates of type 1 and type 2 diabetes, cardiovascular diseases, kidney disorders, and chronic respiratory conditions require constant, repeatable biomarker monitoring. Point-of-care instruments such as continuous glucose monitors (CGMs), portable coagulation analyzers, lipid meters, and cardiac marker assays enable ongoing clinical monitoring without subjecting elderly patients to frequent hospital visits.
Market Challenges
• Regulatory bottlenecks under the EU In vitro diagnostic regulation (EU-IVDR): The full implementation of the European Union’s In Vitro Diagnostic Regulation (EU 2017/746 - IVDR) has fundamentally transformed the regulatory landscape, creating severe commercialization barriers. Under IVDR, the vast majority of POC diagnostic devices previously self-certified by manufacturers under the older IVDD directive now require rigorous, independent conformity assessments by designated Notified Bodies. Due to a persistent shortage of accredited Notified Bodies across Europe, manufacturers face multi-year approval backlogs, soaring clinical trial expenditures, and extensive documentation burdens.• Fragmented reimbursement frameworks and disparate regional healthcare policies: Unlike a single unified market, Europe presents a highly fragmented reimbursement environment across its member countries. Healthcare coverage and health technology assessment (HTA) decisions are governed independently by individual national or regional bodies (e.g., G-BA in Germany, HAS in France, NICE in the UK). A POC device granted reimbursement in one nation often faces lengthy delays or outright rejection in another due to varying cost-effectiveness metrics and local clinical guidelines.
Market Trends
• Integration of AI-driven analytics, telehealth, and virtual ward workflows: The convergence of point-of-care diagnostics with digital health networks is one of the fastest-growing trends across Europe. Modern POC analyzers are increasingly equipped with built-in Bluetooth, Wi-Fi, and cloud infrastructure that automatically transmits diagnostic outputs directly to hospital Electronic Health Record (EHR) platforms and regional telemedicine networks. Combined with artificial intelligence (AI) and machine learning algorithms, these connected devices assist clinicians by highlighting abnormal biomarker patterns and offering automated clinical decision support.• Technological miniaturization and microfluidic lab-on-a-chip advancement: European manufacturers and research institutes are leading a technological transition from conventional qualitative lateral-flow test strips toward advanced, quantitative microfluidic Lab-on-a-Chip (LOC) and isothermal molecular platforms. Microfluidics technology integrates complex sample preparation, reagent mixing, and multi-analyte biosensors onto a single disposable plastic cartridge, requiring only microliter volumes of whole blood, saliva, or nasal swabs.
Point of Care Diagnostics Segmentation
| By Product | Glucose Monitoring Kits | |
| Infectious Diseases Testing Kits | ||
| Pregnancy And Fertility Testing Kits | ||
| Hematology Testing Kits | ||
| Cardiometabolic Monitoring Kits | ||
| Urinalysis Testing Kits | ||
| Cholesterol Test Strips | ||
| Other Products | ||
| By Technology/Platform | Lateral Flow Assays | |
| Molecular Diagnostics (PCR/INAAT) | ||
| Microfluidics & Immunoassays | ||
| Dipsticks & Test Strips | ||
| By End-User | Hospitals & Critical Care Centers | |
| Clinical & Diagnostic Laboratories | ||
| Home Care & Self-Testing | ||
| Europe | Germany | |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Russia | ||
Cardiometabolic monitoring kits are growing rapidly in Europe because the region has a substantial and persistent burden of diabetes, hypertension, cardiovascular disease, and related metabolic risk factors that require regular measurement and follow-up. Europe’s cardiometabolic disease burden creates a direct clinical need for monitoring tools that can provide information about glucose, blood pressure, cholesterol and related indicators close to the patient. Diabetes adds another major requirement for repeated monitoring: WHO/Europe estimates that at least 64 million adults and about 300,000 children and adolescents were living with diabetes in the Region, and notes that approximately one in three people with diabetes remains undiagnosed. WHO/Europe also specifically states that effective blood-glucose control is crucial and that home glucose monitoring for people using insulin can reduce complications. These conditions frequently coexist, meaning that monitoring one risk factor can form part of a wider approach to cardiovascular and metabolic risk management. For example, high blood pressure, abnormal glucose regulation, obesity and abnormal blood lipids are interconnected risk factors addressed through prevention and chronic-disease management. WHO/Europe’s HEARTS and PEN programmes explicitly promote risk assessment, diagnosis and management of cardiovascular disease, hypertension, type 2 diabetes and other noncommunicable diseases within primary care. This environment gives cardiometabolic monitoring kits practical relevance beyond acute diagnosis because measurements can be repeated during routine consultations, chronic-disease reviews, pharmacies, community programmes and home-based self-management. The European population is also ageing, and WHO identifies ageing as an important demographic shift associated with a greater likelihood of multiple chronic conditions. Monitoring kits therefore fit an established healthcare need: detecting abnormal readings, tracking treatment response, identifying deterioration and helping patients and healthcare professionals manage long-term risk. The growth of this category can consequently be linked to the expanding emphasis on earlier detection, continuous risk-factor control, self-management and integrated chronic-disease care rather than dependence on a single diagnostic encounter. Lateral flow assays are growing rapidly in Europe because their simple, rapid and decentralized testing format makes them suitable for bringing diagnostic results closer to patients across clinical, community and self-testing environments. Lateral flow assays are well aligned with the fundamental purpose of point-of-care diagnostics because they can provide results without the infrastructure normally associated with a centralized laboratory. Their operating principle generally involves a sample moving across a membrane and interacting with reagents that produce a visible or instrument-read signal, allowing tests to be designed in compact formats. The technology has already been applied across a wide range of diagnostic areas, including infectious diseases, pregnancy testing and other screening applications. The European Commission describes in vitro diagnostic devices as tests performed on biological samples to determine a person’s health status and specifically includes self-tests and COVID-19 tests among the broad range of IVD applications regulated in Europe. WHO’s 2025 guidance on rapid diagnostic tests covers both professional-use tests and self-tests and identifies applications including HIV, malaria, tuberculosis, SARS-CoV-2, syphilis, hepatitis B, hepatitis C, urine dipsticks, G6PD testing and pregnancy testing. This breadth is important because the same basic decentralized testing concept can be adapted to different diseases and user environments. Lateral flow formats are particularly useful where speed, portability and ease of operation matter, such as pharmacies, outpatient facilities, primary-care locations, emergency settings, community testing programmes and homes. They can also reduce dependence on specialized laboratory infrastructure for selected tests, although positive or uncertain results may still require professional assessment or confirmatory testing depending on the application. WHO emphasizes that diagnostic services are essential not only for diagnosis but also for screening, case management, monitoring and treatment decisions. Europe’s regulatory framework has also become more structured under Regulation (EU) 2017/746, which has applied since May 2022 and introduced risk-based classification, more detailed performance requirements and greater involvement of conformity-assessment bodies. Home care and self-testing are growing rapidly in Europe because healthcare systems are increasingly supporting people in monitoring and managing selected health conditions outside conventional clinical facilities. Home-based testing is becoming more relevant as European healthcare systems manage large populations with chronic diseases while also responding to ageing, accessibility and continuity-of-care requirements. WHO defines self-care as the ability of individuals, families and communities to promote and maintain their health and specifically includes diagnostics among self-care interventions, citing pregnancy self-tests and devices for self-monitoring conditions such as diabetes and hypertension. This is particularly significant in Europe because diabetes and cardiovascular disease require ongoing monitoring rather than isolated diagnostic encounters. WHO/Europe reports that diabetes is one of the most common chronic conditions in the Region and estimates that at least 64 million adults are living with the disease, while also emphasizing blood-glucose control, home monitoring for insulin users and support for self-management. Cardiovascular disease presents another long-term monitoring requirement, with WHO/Europe identifying hypertension as the leading risk factor and noting that approximately one in three adults in the Region has hypertension. Home care can make repeated measurements more convenient by allowing individuals to collect information in their normal environment and share relevant readings with healthcare professionals when appropriate. It can also reduce the need for some routine measurements to occur exclusively during face-to-face appointments, although home testing does not eliminate the need for professional diagnosis and follow-up. Population ageing reinforces this need. WHO identifies rapid population ageing as a major challenge for European health and social systems and notes that older adults are more likely to experience multiple health conditions simultaneously. At the same time, WHO’s 2025 guidance on rapid diagnostic tests specifically addresses accessibility and usability for professional and self-testing environments, highlighting the importance of designs that can be used effectively by older adults and people with disabilities. Prescription-based products are growing rapidly because professional involvement is increasingly important for point-of-care tests that require clinical interpretation, patient selection, treatment decisions or follow-up rather than simple consumer screening. Prescription-based point-of-care diagnostics occupy an important position where the test result is closely connected to a healthcare professional’s assessment and subsequent clinical action. Unlike a purely consumer-oriented screening product, many diagnostic procedures are used as part of a structured care pathway in which a clinician determines whether testing is appropriate, interprets the result alongside symptoms and medical history, and decides whether additional investigation or treatment is required. The European Commission’s framework for in vitro diagnostic medical devices establishes a formal regulatory structure under Regulation (EU) 2017/746, which has applied since May 2022 and introduced risk-based classification, more detailed performance evaluation and stronger involvement of conformity-assessment bodies. This framework is relevant to prescription-linked products because clinical use requires confidence in analytical and clinical performance, labeling, intended purpose and appropriate risk classification. Point-of-care diagnostics are particularly useful when a result can immediately contribute to a clinical decision, including testing in primary care, emergency services, hospitals and other professional environments. WHO states that diagnostics are essential for prevention, screening, diagnosis, case management, monitoring and treatment of both communicable and noncommunicable diseases. Europe’s chronic-disease profile strengthens this professional requirement. WHO/Europe identifies cardiovascular diseases and diabetes among the leading noncommunicable diseases in the Region, while hypertension, high blood glucose, obesity and abnormal metabolic factors require ongoing assessment and management. In these circumstances, diagnostic results can influence medication management, treatment adjustment, referral and additional laboratory investigation, making professional oversight valuable. Prescription-linked testing can also support better integration between point-of-care results and established healthcare records or clinical pathways. Urine is growing rapidly as a point-of-care sample because it is easy to collect non-invasively and can provide clinically useful information across urinary, metabolic, renal, infectious and general health assessments. Urine offers several practical characteristics that make it highly compatible with decentralized diagnostics. Collection normally does not require needles or specialized phlebotomy equipment, and a specimen can be obtained relatively easily in clinics, community settings or the home. WHO explicitly identifies urine tests among the examples of in vitro diagnostics and includes urine dipstick testing within its rapid diagnostic test accessibility guidance. Urinalysis can provide information about multiple physiological or pathological indicators, depending on the test format, including glucose, protein, blood, ketones, leukocytes, nitrites, pH and other parameters. This makes urine particularly useful for screening and preliminary assessment rather than being restricted to one disease category. The sample is also relevant to several conditions that require recurring healthcare attention. Kidney disease, diabetes and urinary tract disorders can all involve urine-based investigations, while urine testing can contribute to identifying abnormalities that require further clinical evaluation. WHO/Europe notes that diabetes can cause kidney disease as a complication and emphasizes the importance of complication screening and care as part of diabetes management. WHO also describes blood and urine sampling as components of the standardized STEPwise approach used to measure metabolic risk factors such as raised blood glucose, cholesterol and kidney-related indicators. The ease of collecting urine makes it suitable for situations where repeated or decentralized screening is useful, and dipstick formats can provide rapid visual or instrument-assisted results without requiring a conventional laboratory analyzer for every preliminary test. WHO’s diagnostic guidance emphasizes that diagnostics are needed for screening, diagnosis, case management and monitoring, which supports the value of accessible sample types that can be used at different healthcare levels. Urine also fits the broader movement toward self-testing and decentralized healthcare because certain urine-based tests are already familiar to consumers, including pregnancy tests. The European Commission explicitly lists pregnancy self-tests among IVDs regulated under the European framework.
to Download this information in a PDF
Point of Care Diagnostics Market Regional Insights
Spain is showing strong potential within the European point-of-care diagnostics landscape because its ageing population, substantial chronic-disease burden and established healthcare system create sustained demand for accessible monitoring and decentralized diagnostic services. Spain’s demographic and disease profile provides several concrete reasons for strong development of point-of-care diagnostics. The 2025 Spain Country Health Profile reports that cardiovascular diseases accounted for 26.6% of deaths in Spain in 2023, making cardiovascular conditions one of the country’s most important causes of mortality. The same profile reports that 44% of Spanish men and 48% of Spanish women aged 65 and over had multiple chronic conditions in the referenced survey data. This combination of cardiovascular disease and multimorbidity creates a healthcare environment in which regular monitoring and timely diagnostic assessment are important. Spain also has a substantial older population, and previous European health-system data documented the increasing proportion of people aged 65 and above and the high prevalence of chronic conditions among older adults. Ageing is particularly relevant to point-of-care diagnostics because older patients are more likely to require repeated monitoring for conditions such as diabetes, hypertension, cardiovascular disease and kidney-related complications. WHO/Europe identifies population ageing as one of the major pressures affecting European health systems and notes that multiple chronic conditions become more common with increasing age. Spain’s cardiovascular burden also creates a need for monitoring risk factors that can be assessed through decentralized diagnostic approaches. WHO/Europe identifies hypertension as the leading risk factor driving cardiovascular disease in the European Region and emphasizes early detection and control of cardiovascular risk factors. Diabetes adds another relevant application area, as WHO/Europe identifies blood-glucose control, complication screening and self-management as important components of diabetes care.
to Download this information in a PDF
Companies Mentioned
- Abbott Laboratories
- Danaher
- F. Hoffmann-La Roche AG,
- Siemens Healthineers
- OraSure Technologies
- Thermo Fisher Scientific Inc
- QIAGEN N.V.
- QuidelOrtho Corporation
- Becton, Dickinson and Company
- bioMérieux
- EKF Diagnostics
- Werfen S.A.
Table of Contents
- 1. Executive Summary
- 2. Market Dynamics
- 2.1. Market Drivers & Opportunities
- 2.2. Market Restraints & Challenges
- 2.3. Market Trends
- 2.4. Supply chain Analysis
- 2.5. Policy & Regulatory Framework
- 2.6. Industry Experts Views
- 3. Research Methodology
- 3.1. Secondary Research
- 3.2. Primary Data Collection
- 3.3. Market Formation & Validation
- 3.4. Report Writing, Quality Check & Delivery
- 4. Market Structure
- 4.1. Market Considerate
- 4.2. Assumptions
- 4.3. Limitations
- 4.4. Abbreviations
- 4.5. Sources
- 4.6. Definitions
- 5. Economic /Demographic Snapshot
- 6. Europe Point of Care Diagnostics Market Outlook
- 6.1. Market Size By Value
- 6.2. Market Share By Country
- 6.3. Market Size and Forecast, By Product
- 6.4. Market Size and Forecast, By Technology/Platform
- 6.5. Market Size and Forecast, By End-User
- 6.6. Market Size and Forecast, By Mode Of Purchase
- 6.7. Market Size and Forecast, By Sample
- 6.8. Germany Point of Care Diagnostics Market Outlook
- 6.8.1. Market Size by Value
- 6.8.2. Market Size and Forecast By Product
- 6.8.3. Market Size and Forecast By Technology/Platform
- 6.8.4. Market Size and Forecast By End-User
- 6.9. United Kingdom (UK) Point of Care Diagnostics Market Outlook
- 6.9.1. Market Size by Value
- 6.9.2. Market Size and Forecast By Product
- 6.9.3. Market Size and Forecast By Technology/Platform
- 6.9.4. Market Size and Forecast By End-User
- 6.10. France Point of Care Diagnostics Market Outlook
- 6.10.1. Market Size by Value
- 6.10.2. Market Size and Forecast By Product
- 6.10.3. Market Size and Forecast By Technology/Platform
- 6.10.4. Market Size and Forecast By End-User
- 6.11. Italy Point of Care Diagnostics Market Outlook
- 6.11.1. Market Size by Value
- 6.11.2. Market Size and Forecast By Product
- 6.11.3. Market Size and Forecast By Technology/Platform
- 6.11.4. Market Size and Forecast By End-User
- 6.12. Spain Point of Care Diagnostics Market Outlook
- 6.12.1. Market Size by Value
- 6.12.2. Market Size and Forecast By Product
- 6.12.3. Market Size and Forecast By Technology/Platform
- 6.12.4. Market Size and Forecast By End-User
- 6.13. Russia Point of Care Diagnostics Market Outlook
- 6.13.1. Market Size by Value
- 6.13.2. Market Size and Forecast By Product
- 6.13.3. Market Size and Forecast By Technology/Platform
- 6.13.4. Market Size and Forecast By End-User
- 7. Competitive Landscape
- 7.1. Competitive Dashboard
- 7.2. Business Strategies Adopted by Key Players
- 7.3. Porter's Five Forces
- 7.4. Company Profile
- 7.4.1. Abbott
- 7.4.1.1. Company Snapshot
- 7.4.1.2. Company Overview
- 7.4.1.3. Financial Highlights
- 7.4.1.4. Geographic Insights
- 7.4.1.5. Business Segment & Performance
- 7.4.1.6. Product Portfolio
- 7.4.1.7. Key Executives
- 7.4.1.8. Strategic Moves & Developments
- 7.4.2. F. Hoffmann-La Roche Ltd.
- 7.4.3. Siemens Healthineers AG
- 7.4.4. QuidelOrtho Corporation
- 7.4.5. Danaher
- 7.4.6. Becton, Dickinson and Company
- 7.4.7. Thermo Fisher Scientific
- 7.4.8. bioMérieux
- 7.4.9. EKF Diagnostics
- 7.4.10. QIAGEN
- 7.4.11. Werfen S.A.
- 7.4.12. OraSure Technologies
- 8. Strategic Recommendations
- 9. Annexure
- 9.1. FAQ`s
- 9.2. Notes
- 10. Disclaimer
Table 2: Top 10 Counties Economic Snapshot 2024
Table 3: Economic Snapshot of Other Prominent Countries 2022
Table 4: Average Exchange Rates for Converting Foreign Currencies into U.S. Dollars
Table 5: Europe Point of Care Diagnostics Market Size and Forecast, By Product (2020 to 2031F) (In USD Billion)
Table 6: Europe Point of Care Diagnostics Market Size and Forecast, By Technology/Platform (2020 to 2031F) (In USD Billion)
Table 7: Europe Point of Care Diagnostics Market Size and Forecast, By End-User (2020 to 2031F) (In USD Billion)
Table 8: Europe Point of Care Diagnostics Market Size and Forecast, By Mode Of Purchase (2020 to 2031F) (In USD Billion)
Table 9: Europe Point of Care Diagnostics Market Size and Forecast, By Sample (2020 to 2031F) (In USD Billion)
Table 10: Germany Point of Care Diagnostics Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)
Table 11: Germany Point of Care Diagnostics Market Size and Forecast By Technology/Platform (2020 to 2031F) (In USD Billion)
Table 12: Germany Point of Care Diagnostics Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)
Table 13: United Kingdom (UK) Point of Care Diagnostics Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)
Table 14: United Kingdom (UK) Point of Care Diagnostics Market Size and Forecast By Technology/Platform (2020 to 2031F) (In USD Billion)
Table 15: United Kingdom (UK) Point of Care Diagnostics Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)
Table 16: France Point of Care Diagnostics Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)
Table 17: France Point of Care Diagnostics Market Size and Forecast By Technology/Platform (2020 to 2031F) (In USD Billion)
Table 18: France Point of Care Diagnostics Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)
Table 19: Italy Point of Care Diagnostics Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)
Table 20: Italy Point of Care Diagnostics Market Size and Forecast By Technology/Platform (2020 to 2031F) (In USD Billion)
Table 21: Italy Point of Care Diagnostics Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)
Table 22: Spain Point of Care Diagnostics Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)
Table 23: Spain Point of Care Diagnostics Market Size and Forecast By Technology/Platform (2020 to 2031F) (In USD Billion)
Table 24: Spain Point of Care Diagnostics Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)
Table 25: Russia Point of Care Diagnostics Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)
Table 26: Russia Point of Care Diagnostics Market Size and Forecast By Technology/Platform (2020 to 2031F) (In USD Billion)
Table 27: Russia Point of Care Diagnostics Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)
Table 28: Competitive Dashboard of top 5 players, 2025
Figure 2: Europe Point of Care Diagnostics Market Share By Country (2025)
Figure 3: Germany Point of Care Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 4: United Kingdom (UK) Point of Care Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 5: France Point of Care Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 6: Italy Point of Care Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 7: Spain Point of Care Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 8: Russia Point of Care Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 9: Porter's Five Forces of Global Point of Care Diagnostics Market
Point of Care Diagnostics Market Research FAQs
Related Reports
One individual can access, store, display, or archive the report in Excel format but cannot print, copy, or share it. Use is confidential and internal only. License information
One individual can access, store, display, or archive the report in PDF format but cannot print, copy, or share it. Use is confidential and internal only. License information
Up to 10 employees in one region can store, display, duplicate, and archive the report for internal use. Use is confidential and printable. License information
All employees globally can access, print, copy, and cite data externally (with attribution to Bonafide Research). License information
Safe and Secure SSL Encrypted
Quick Contacts
Want to customize this report?
We offer 10% Free Customization at the time of purchase
Get Free Customization
Our Clients
Budget constraints? Get in touch with us for special pricing
Request DiscountOrder Detail
- Order Placed (23 September, 2026)
- Notify To Team (23 September, 2026)
- Report updation (24 September, 2026)
- Report Quality Check (24 September, 2026)
- Report Dispatch (25 September, 2026)
- Hard Copy
Recently Viewed Products
Europe Point of Care Diagnostics Market Outlook, 2031
We are friendly and approachable, give us a call.